ARTIFICIAL INTELLIGENCE:-NEW REVOLUTION IN THE FIELD OF PHARMACY

ARTIFICIAL INTELLIGENCE:-  NEW REVOLUTION IN THE FIELD OF PHARMACY                                                                        

 

  INTRODUCTION 

(1) The term Artificial intelligence is also known as Machine Intelligence and it is very commonly confused with robotics and automation.                                                                                                       

(2) Robotics is simply the creation of machine that carry out difficult task while AI refers to the exhibition of human like behavior or intelligence by any computer or machine.                                       

(3) Recently Food and Drug Administration (FDA) had approved nearly 700 AI or machine learning enabled devices in the US.                                                                                                                       

(4) This defines the broad nature of AI and it can be applied to nearly every aspects of the pharmaceutical and healthcare industry to enhance the data processing and functioning.

WHY AI IN PHARMACY?

AI AND DEVELOPMENT OF PHARMACEUTICALS 

(1) Top pharmaceuticals companies are collaborating with AI vendors and leveraging AI in their manufacturing process for research and development.                                                                              

(2) The Mckinsey Global Institute estimates that AI and Machine learning in the pharmaceutical industry could generate nearly $100B annually in US health care system.                                                  

(3) GNS Healthcare uses AI Machine Software known as Reverse Engineering and Forward Simulation(REFS) which determines the cause & effect of relationship between various types of data.        

(4) In Drug design a company known as Atomwise developed the first deep learning neural network for structure base drug design.                                                                                                                    

(5) Insilico Medicine with the company Pharm AI claimed that they applied Generative Adversarial Networks(GAN) which can generate new molecular structures.

AI IN HOSPITAL AND COMMUNITY PHARMACIES

(1)Chatbots can be used to increase the efficiency of service delivery and they are capable of mimicking interactions between customers and health professionals.

(2)Chatbots are capable of automatically resolving customer complains and queries.

(3)AI can also be useful in the inventory management as retail pharmacist, imaging being able to predict what your patience will need in the nearest future, stocking them and remind the drug needs.

(4)Walgreen made a partnership with Medline, a telehealth firm to create a software to help patients interact with healthcare professionals through video chat.

ROLE OF AI IN PHARMACOVIGILANCE

                

CONCLUSION

✅While there are many ways in which AI can be used within the pharmaceutical industry to better the   ways in which health professionals can work, it can also optimize the sector, in order to promote a far   better health experience for those who need it.                                                                                                                                                                                                                                                     

✅AI has the capability to optimize marketing strategies, benefits manufacturing processes and drug   clinical trials, so it will be adopted for further use in the future.

 REFERENCES

1. Deep Mind’s health team. [cited 2022 13 June]; Available from: https://www.deepmind.com/blog/deepminds-health-team-joins-google-health.

2. Fleming, N., How artificial intelligence is changing drug discovery. Nature, 2018. 557(7706): p. S55-S55. [DOI ] [PubMed ] [Google Scholar].

3. Ferrero, E., Dunham I., and Sanseau P., In silico prediction of novel therapeutic targets using gene disease association data. Journal of translational medicine, 2017. 15(1): p. 1-16. [DOI ] [ PMC free article ] [PubMed ] [Google Scholar].

4. Yildirim, O., et al. , Opportunities and challenges for drug development: public–private partnerships, adaptive designs and big data. Frontiers in pharmacology, 2016. 7: p. 461. [DOI ] [PMC free article ] [PubMed ] [Google Scholar].